CHISON MEDICAL(SH:688358) Sou Hu Cai Jing·2025-09-08 10:19Core Viewpoint - Xiangsheng Medical (688358) is focusing on innovation and development in the ultrasound field, with significant investments in R&D and a commitment to expanding its product offerings and market presence [2][6]. R&D Investment - In the first half of 2025, the company invested 37.61 million RMB in R&D, accounting for 15.93% of its revenue [2]. - The company has received 43 foreign market access licenses this year, enhancing its overseas market share [2]. Product Development - The company has developed the "AI + Ultrasound Robot" product, which integrates visual recognition and robotic control technologies to address mass screening challenges for malignant tumors [3]. - The "Breast AI Ultrasound Robot" has received medical device testing reports, targeting breast cancer, and aims to establish a comprehensive breast health management model in China [3]. Technological Ecosystem - The company has established a collaborative system in the "I + Robot" field, integrating technology for enhanced diagnostic precision and operational efficiency [4]. Veterinary Ultrasound Products - The company has launched the SonoVet series for veterinary ultrasound, addressing traditional challenges in image resolution and operational dependency on experience [5]. Financial Performance - For the first half of 2025, the company reported a main revenue of 236 million RMB, a year-on-year decrease of 4.61%, and a net profit of approximately 69.70 million RMB, down 14.32% [6]. - The second quarter of 2025 saw a main revenue of 108 million RMB, a slight increase of 1.37% year-on-year, but a net profit decline of 21.57% [6]. Market Outlook - Analysts have provided profit forecasts for the company, with expected net profits of 165 million RMB in 2025, 192 million RMB in 2026, and 222 million RMB in 2027 [6].